JP2024537192A5 - - Google Patents

Info

Publication number
JP2024537192A5
JP2024537192A5 JP2024520926A JP2024520926A JP2024537192A5 JP 2024537192 A5 JP2024537192 A5 JP 2024537192A5 JP 2024520926 A JP2024520926 A JP 2024520926A JP 2024520926 A JP2024520926 A JP 2024520926A JP 2024537192 A5 JP2024537192 A5 JP 2024537192A5
Authority
JP
Japan
Prior art keywords
subject
cancer
composition
cells
gsk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024520926A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024537192A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/077746 external-priority patent/WO2023060226A1/en
Publication of JP2024537192A publication Critical patent/JP2024537192A/ja
Publication of JP2024537192A5 publication Critical patent/JP2024537192A5/ja
Pending legal-status Critical Current

Links

JP2024520926A 2021-10-07 2022-10-07 がんを処置するためのｗｎｔシグナル伝達を増強するための組成物および方法 Pending JP2024537192A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163253380P 2021-10-07 2021-10-07
US63/253,380 2021-10-07
PCT/US2022/077746 WO2023060226A1 (en) 2021-10-07 2022-10-07 Compositions and methods for enhancing wnt signaling for treating cancer

Publications (2)

Publication Number Publication Date
JP2024537192A JP2024537192A (ja) 2024-10-10
JP2024537192A5 true JP2024537192A5 (enExample) 2025-10-17

Family

ID=83978871

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024520926A Pending JP2024537192A (ja) 2021-10-07 2022-10-07 がんを処置するためのｗｎｔシグナル伝達を増強するための組成物および方法

Country Status (8)

Country Link
US (2) US12440497B2 (enExample)
EP (1) EP4412614A1 (enExample)
JP (1) JP2024537192A (enExample)
CN (1) CN118338903A (enExample)
AU (1) AU2022361519A1 (enExample)
CA (1) CA3233974A1 (enExample)
IL (1) IL311934A (enExample)
WO (1) WO2023060226A1 (enExample)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008106408A1 (en) * 2007-02-27 2008-09-04 Cedars-Sinai Medical Center Treatment of cancer with bio and chemotherapy
JPWO2006073202A1 (ja) * 2005-01-04 2008-08-07 国立大学法人金沢大学 ＧＳＫ３β阻害効果に基づくがんの抑制および抗がん剤の評価方法
WO2007150030A2 (en) 2006-06-23 2007-12-27 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
JP2016538342A (ja) * 2013-11-18 2016-12-08 イエール ユニバーシティ トランスポゾンを使用する組成物および方法
US20230241000A1 (en) * 2020-06-30 2023-08-03 The Regents Of The University Of California Gsk3 inhibitor-loaded nano formulations as a cancer immunotherapeutic

Similar Documents

Publication Publication Date Title
JP2024543505A5 (enExample)
JP2001010976A (ja) 中枢神経系（ｃｎｓ）の原発性および二次性腫瘍を治療する方法並びに組成物
US20200253868A1 (en) Cell autophagy inhibitor and preparation method therefor and application thereof
CN110665003A (zh) 一种双载药无载体纳米粒及其制备方法
Chen et al. Intelligent hydrogels for treating malignant melanoma
JP2021535163A (ja) タウロリジン加水分解産物による神経芽細胞腫治療
CN108503676B (zh) 用于癌症治疗的果糖类似物及其组合物
US20140135272A1 (en) Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment
JP2014221752A (ja) ガン幹細胞に対する分化促進薬及び脳腫瘍治療薬
WO2018064851A1 (zh) 低剂量西地那非作为抗肿瘤药物的应用
AU2009240908B2 (en) Methods of administering antitumor agent comprising deoxycytidine derivative
CN101588800B (zh) 给药抗肿瘤化合物的方法
US20210308106A1 (en) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
JP6564952B2 (ja) 腫瘍を予防・治療する医薬およびその用途
CN106539811B (zh) 环二核苷酸cGAMP在防治抗肿瘤化药诱发的并发症或降低化疗药诱导的毒副作用中的应用
EP3965734A1 (en) Method for increasing cancer patient's haemoglobin level
US20250221967A1 (en) Compositions and methods for the treatment of cancer and other proliferative diseases
US20240139113A1 (en) Lipid nanoparticle with target integrin function and uses thereof
JP2021533107A (ja) 癌を治療するための併用療法
RU2238731C2 (ru) Способ лечения метастатических поражений головного мозга
CN118045043A (zh) 一种纳米药物的配方优化方法及应用
WO2026039718A1 (en) Cancer treatment using 5,6-dihydro-4h-benzo[de] quinoline-camptothecin
HK40104393A (en) [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid (roxadustat) for the treatment of chemotherapy-induced anemia (cia)
HK40113965A (en) [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid (roxadustat) for the treatment of chemotherapy-induced anemia (cia)
HK40113623A (en) [(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid (roxadustat) for the treatment of chemotherapy-induced anemia (cia)